Company Profile

Uluru Inc
Profile last edited on: 10/3/2023      CAGE: 59U62      UEI: N24WUMUHT5V9

Business Identifier: Innovative wound care and drug delivery systems based on firm's patented technologie
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

4452 Beltway Drive
Addison, TX 75001
   (214) 905-5145
Location: Single
Congr. District: 24
County: Dallas

Public Profile

Defining the firm's operations as tackling improving lives of patients by delivering comprehensive solutions that optimize outcomes for the key stakeholders in healthcare systems -- patients, providers and payers -- Uluru management describe the firm as specialty medical technology company committed to developing and commercializing innovative wound care and drug delivery systems based on the firm's patented technologies. Uluru indicate having already developed two patented technology platforms: Altrazeal® -- new class of material designed to optimize the wound bed environment and accelerate healing and OraDisc - a novel, patented, cost-effective, commercially-viable, water-erodible pharmaceutical carrier device, the multi-layered device may be applied to mucosal surfaces, and adheres immediately, delivering actives to treat specific localized diseases/disorders. OraDisc technology can deliver drugs systemically across the mucosal surface or for release of drugs into the oral cavity. The device causes minimum discomfort, is easy to apply and capable of providing tailored erosion rates to deliver therapeutics over different time intervals.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2022 2 Army $1,267,448
Project Title: Developing an Ideal First Use Agent to Prevent Sepsis in Trauma Wounds During Care Under Fire

Key People / Management

  Howard Callahan -- Quality Control Manager

  Vaidehi Shah -- Chairman, President and CEO

Company News

There are no news available.